ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of “Moderate Buy” by Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $12.50.

Several analysts recently commented on ALXO shares. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research note on Tuesday, August 13th. Stifel Nicolaus reiterated a “hold” rating and set a $3.00 price target (down from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. UBS Group lowered their price target on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Tuesday, November 12th. Finally, Lifesci Capital downgraded ALX Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 31st.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co purchased a new position in ALX Oncology during the first quarter worth $27,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after acquiring an additional 5,200 shares during the last quarter. SG Americas Securities LLC increased its position in ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after purchasing an additional 6,888 shares in the last quarter. Hsbc Holdings PLC acquired a new position in ALX Oncology in the 2nd quarter valued at about $63,000. Finally, GSA Capital Partners LLP purchased a new position in ALX Oncology in the 3rd quarter valued at about $88,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

ALX Oncology Price Performance

ALX Oncology stock opened at $1.51 on Thursday. The company has a market cap of $79.64 million, a P/E ratio of -0.51 and a beta of 1.03. ALX Oncology has a one year low of $1.19 and a one year high of $17.83. The business has a fifty day moving average of $1.56 and a two-hundred day moving average of $4.64. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.